Another Rituximab Debuts In India But No Price Contest?
This article was originally published in PharmAsia News
Executive Summary
The privately owned Indian firm Hetero has launched rituximab, its biosimilar version of Roche's MabThera/Rituxan, in India, trailing a clutch of local peers onto the market, although it is not yet clear what price advantages it may have over rivals.